Introduction In this article we pose the questions of how to manage PDPH in the COVID-19 positive patient and more specifically, the use of epidural blood patch (EBP). EBP in COVID-19 Patients Carries Additional Risks A primary concern in the use of EBP in these patients is the possibility of seeding the virus in the CNS. Another important concern is related to the known hypercoagulable state in COVID-19 positive patients and associated organ dysfunction that may alter the metabolism of anticoagulants. The safety of the providers performing the EBP, the position of the patient and choices for image guidance (blind, fluoroscopic) are also key considerations to review. It is also important to explore the current state of knowledge about using allogenic instead of autologous blood as well as emerging techniques to eliminate the coronavirus from the blood. Other Options for Treating PDPH in COVID-19 Patients EBP is usually considered after the failure of conservative and pharmacological treatments. Because of the additional risks of EBP in COVID-19 patients it is important to also consider less traditional pharmacological treatments such as theophylinnes and cosyntropin that may offer some additional benefit for COVID-19 patient. Finally, other interventions other than EBP should also be considered including occipital nerve blocks, sphenopalatine ganglion blocks (infratemporal or transnasal). Clinical Recommendation We conclude our article with recommendations on how to approach the treatment of PDPH for their COVID-19 patients.
|Original language||English (US)|
|Issue number||4 Special Issue|
|State||Published - Aug 2020|
- Epidural Blood Patch
- Post-dural Puncture Headache
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine